3. Anticoagulant Safety Remains a Problem

4. Emergency Hospitalizations for Adverse Drug Events

6. Comparative Pharmacology

7. Inducers and Inhibitors of Cytochrome P450 3A4 and P-gp

8. Novel Anticoagulants for Stroke Prevention in AF

9. Trials With NOACs vs Warfarin in AF

12. All NOACs and Stroke or SE Event

14. ENGAGE AF-TIMI 48: Primary End Point Stroke/Systemic Embolic Event (2
ENGAGE AF-TIMI 48: Primary End Point Stroke/Systemic Embolic Event (2.8-y median follow-up)

15. ENGAGE AF-TIMI 48 Bleeding

18. Who Should Remain on Warfarin?

19. EINSTEIN DVT/PE Study Designs

20. Switching From Warfarin to NOACs

21. Adverse Events

22. Summary Benefits of NOACs

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)